17 January 2019

Touchlight welcomes Anjum Ahmad as Chief Financial Officer

Anjum Ahmad brings extensive insight in the UK’s life sciences sector having been the longstanding Group Finance Director of Touchstone Innovations Plc (formerly Imperial Innovations) – the AIM listed venture capital investor in early stage science.

In his former role at Touchstone he was one of the four-person senior executive team, presenting over £200m of investment opportunities in the therapeutics/biotech field to the Luxembourg Board, managing the corporate finance activity for an equity raise of £250m, responsible for the finance/treasury tax operations, conducting portfolio company asset valuations, and presenting the interim/year end results alongside their CEO. He was also responsible for their I.T. and H.R. functions.

Prior to Imperial Innovations he held finance positions within a tech start-up and GSK.

- ENDS -

About Touchlight

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.

dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.

Issued for and on behalf of Touchlight by Instinctif Partners.

For more information please contact:

Jonny Ohlson, CEO Tim Watson / Agnes Stephens /
Tommy Duncan, CBO Katie Duffell
E: info@touchlight.com E: touchlight@instinctif.com
T: +44 20 8481 9200 T: +44 20 7457 2020